Vanguard Group
AST.WS

Vanguard Group’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

Vanguard Group’s Portfolio AST.WS Stock Details AST.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-89,777
Closed -$45K – 4133
2017
Q2 		$45K Hold
89,777
– – ﹤0.01% 4033
2017
Q1 		$39K Hold
89,777
– – ﹤0.01% 4038
2016
Q4 		$49K Hold
89,777
– – ﹤0.01% 4038
2016
Q3 		$45K Hold
89,777
– – ﹤0.01% 4040
2016
Q2 		$18K Buy
+89,777
New +$46.8K ﹤0.01% 4120

Vanguard Group's AST.WS Position: Q3 2017 in Review

Vanguard Group sold out of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) in Q3 2017, closing a stake of 89,777 shares — an estimated $45K sold.

Vanguard Group first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $49K in Q4 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Vanguard Group reported no remaining Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position as of Q3 2017 after selling out during the quarter.
  • Vanguard Group sold 89,777 Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) shares in Q3 2017, an estimated $45K.
  • Vanguard Group first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and held it in 5 quarters.
  • Vanguard Group's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $49K in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q3 2017.

Based on Vanguard Group's 13F filing for Q3 2017, filed 14 Nov 2017.